Results 281 to 290 of about 3,854,141 (349)
British Journal of Anaesthesia, 2018 Background The biological perturbation associated with psychological and surgical stress is implicated in cancer recurrence. Preclinical evidence suggests that beta‐blockers can be protective against cancer progression.
Maria Angeles Lopez-Olivo +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Misconceptions and Facts About Beta-Blockers
American Journal of Medicine, 2019Beta-blockers are commonly used medications, and they have been traditionally considered "cardioprotective." Their clinical use appears to be more widespread than the available evidence base supporting their role in cardioprotection.
Edgar Argulian +2 more
exaly +2 more sources
Beta-Blockers for Migraine Prevention: a Review Article
Current Treatment Options in Neurology, 2019Arash Danesh, P. Gottschalk
exaly +2 more sources
Beta-blockers: Historical perspective and mechanisms of action.
Revista Española de Cardiología, 2019Beta-blockers are widely used molecules that are able to antagonize β-adrenergic receptors (ARs), which belong to the G protein-coupled receptor family and receive their stimulus from endogenous catecholamines.
E. Oliver, F. Mayor, P. D’Ocon
semanticscholar +1 more source
The vasodilatory beta-blockers
Current Hypertension Reports, 2007Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that beta-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions.
Michala E, Pedersen, John R, Cockcroft
openaire +2 more sources
Role of beta-blockers in cardiovascular disease in 2019.
Revista Española de Cardiología, 2019Beta-blockers are the cornerstone of treatment for various cardiovascular conditions. Although their effects have classically been considered to be driven by their antagonistic and competitive action on beta-adrenergic receptors, nowadays it is known ...
Juan Martínez-Milla +3 more
semanticscholar +1 more source
European Journal of Clinical Pharmacology, 1982
In a randomized, blind crossover study in 14 hypertensive patients with asthma, involving placebo and chronically administered (3 weeks) equipotent beta1-blocking doses of atenolol 100 mg once daily and metoprolol 100 mg bid, atenolol and metoprolol produced a similar fall in blood pressure.
D S, Lawrence +3 more
openaire +2 more sources
In a randomized, blind crossover study in 14 hypertensive patients with asthma, involving placebo and chronically administered (3 weeks) equipotent beta1-blocking doses of atenolol 100 mg once daily and metoprolol 100 mg bid, atenolol and metoprolol produced a similar fall in blood pressure.
D S, Lawrence +3 more
openaire +2 more sources
2015
Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of ...
C. Gelmetti, R. Cavalli
openaire +4 more sources
Infantile hemangiomas (IHs) are the most common tumors in infancy. Their typical natural history is characterized by an early rapid growth in the first months of life and by a slow spontaneous involution in the first years of life. Even though spontaneous regression of IHs could suggest therapeutic abstention, systemic treatment is the therapy of ...
C. Gelmetti, R. Cavalli
openaire +4 more sources
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
New England Journal of MedicineBACKGROUND Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and ...
T. Yndigegn +18 more
semanticscholar +1 more source
BJOG: An International Journal of Obstetrics & Gynaecology, 1981
DRUGS that competitively antagonize the effects of catecholamines at beta-adrenoreceptors have been in clinical use since the mid-1960s.
openaire +3 more sources
DRUGS that competitively antagonize the effects of catecholamines at beta-adrenoreceptors have been in clinical use since the mid-1960s.
openaire +3 more sources